RxDoctor Payments Data

Faraidoon Golyan, DO

Cardiovascular Disease · Forest Hills, NYNPI 1174559926

Payments from drug & device makers

$10,266in general payments, 2019–2025

Across 199 payments — averaging $51.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$5K
  • Medtronic$1K
  • Novartis$691
  • Merck$479
  • Alnylam Pharmaceuticals Inc.$394
  • AstraZeneca$368
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$4,37443%
  • Travel & lodging$1,32413%
  • Food & beverage$4,54944%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,266 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$997,384
Medicare patients
1,090
Services billed
10,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban399$354,459
EntrestoSacubitril/Valsartan159$147,798
JardianceEmpagliflozin136$102,365
FarxigaDapagliflozin Propanediol103$97,588
XareltoRivaroxaban99$69,615
OzempicSemaglutide35$32,617
JanuviaSitagliptin Phosphate40$26,453
RybelsusSemaglutide17$23,526
MultaqDronedarone Hcl24$18,275
JanumetSitagliptin Phos/Metformin Hcl18$16,175
TradjentaLinagliptin20$12,051
Metoprolol Succinate785$9,398
Breo ElliptaFluticasone/Vilanterol21$8,258
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,170
Atorvastatin Calcium460$3,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$354,459399 claims
NovartisEntresto$691$147,798159 claims
Boehringer IngelheimJardiance, Tradjenta$77$114,416156 claims
AstraZenecaFarxiga$368$97,588103 claims
Johnson & JohnsonXarelto$357$69,61599 claims
Novo NordiskOzempic, Rybelsus$20$56,14352 claims
MerckJanuvia, Janumet$479$42,62958 claims
Sanofi-aventis U.S. LLCMultaq$118$18,27524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →